首页 产业/市场分类 出版商一览 Email 通知 GII媒体代理会议 公司简介 联络我们
- English Japanese Korean
首页 > 市场调查报告书 > 医疗设备 > 体外诊断设备 > 欧洲的重点照护诊断检查市场
产业/市场分类
医疗设备 (4510)
内视镜检查设备 (158)
分子呈像/呈影剂 (28)
心血管设备 (332)
可抛式医学设备 (76)
核子医学 (80)
病患监测 (382)
眼科设备 (102)
伤口护理 (159)
超音波 (54)
齿科设备 (174)
导管 (231)
整形外科 (335)
医学影像诊断 (414)
体外诊断设备 (476)
CT/MRI/X光 (172)
e保健 (321)
市场调查报告书

欧洲的重点照护诊断检查市场

European Point of Care Diagnostic Testing Markets

出版商 Trimark Publications
出版日期 2011年09月 商品编码 210402
内容信息 英文 179 Pages
价格
US $ 3400 PDF by E-mail (Single User License)
US $ 6800 PDF by E-mail (Enterprise License)


欧洲的重点照护诊断检查市场 是由出版商Trimark Publications在2011年09月所出版的。 这份英文市场调查报告书包含179 Pages 价格从美金3400起跳。

简介

重点照护检查（POCT）为病患在医院和诊所等地点可实施诊断检查，做为可立即提供诊断结果的方式而急速扩展。

本报告，调查分析欧洲的POCT产品市场，详细分析各市场区块，同时汇整最新的技术进步、收益动向、市场成长率、地区别动向等，由下列摘要形式阐述。

第1章 概要

第2章 欧洲的重点照护检查（POCT）市场背景

  • 重点照护检查的背景与定义
  • POCT应用领域
    • 基层照护
    • 手术室
    • 集中治疗室
    • 事故・急救
    • 病患运输设备
    • 居家医疗
    • 运动医学
  • 定性市场分析
  • 法律规范环境、问题、课题
  • 欧洲的医疗制度概要
  • 重点照护检查产品的采购程序
  • EU的二级照护结构与组织
  • 产品价格政策与课题
  • 技术进步与发展
  • 将来动向与发展

第3章 欧洲的血糖值POCT市场

  • 背景
  • 种类
  • 市场区块
  • 新兴技术
  • 血糖值监控系统检视
  • 市占率分析

第4章 欧洲的血液气体・电解质POCT市场

  • 背景
  • 市场区块
  • 应用
  • 新兴技术
  • 市场收益分析
  • 市占率分析

第5章 欧洲的即时凝固检查市场

  • 背景
  • 血液凝固检查
  • 定性分析
  • 即时凝固分析装置检视
  • 市场收益分析
  • 市占率分析

第6章 欧洲的POC心脏生物标记检查市场

  • 背景
  • 心脏标记检查
  • 新兴标记
  • 定性分析
  • 心脏生物标记分析装置检视
  • 市场收益分析
  • 市占率分析

第7章 POC药物滥用检查市场

  • 背景
  • 种类
  • 定性分析
  • 分析装置检视
  • 市场收益分析
  • 市占率分析

第8章 欧洲的POC传染病检查市场

  • 背景
  • 种类
  • 诊断平台
  • 新兴技术
  • 定性分析
  • 传染病检查装置检视
  • 市场收益分析
  • 市占率分析

第9章 欧洲的POC尿液分析

  • 背景
  • 新兴技术
  • 检查检视
  • 市场收益分析
  • 市占率分析

第10章 欧洲的POC怀孕检查市场

  • 背景
  • 装置检视
  • 市场收益分析
  • 市占率分析

第11章 欧洲的POC粪便潜血检查市场

  • 背景
  • 装置检视
  • 市场收益分析
  • 市占率分析

第12章 欧洲的POC胆固醇检查市场

  • 背景
  • 胆固醇检查装置
  • 市场收益分析
  • 市占率分析

第13章 主要供应商的档案数据

第14章 省略语解说

图表

目录

Abstract

image1

Point of care testing (POCT) enables diagnostic tests to be performed rapidly while the patient remains at the point of care facility, such as a hospital, health clinic, doctor' s office or another near-patient venue. POCT is rapidly being recognized as a method of providing the results of the diagnostic tests immediately, rather than waiting hours or even days for outside lab results to arrive, thus improving patient outcomes. This report analyzes the European market for POCT products, a major component of the overall European in vitro diagnostics (IVD) category. This study reviews in detail the key sub-segments of the point of care diagnostics market including: blood glucose, blood gas and electrolytes, rapid coagulation, cardiac markers, substance abuse, infectious diseases, urine strip, pregnancy, fecal occult, cholesterol, and many others. For each of the individual sub-segments, this study examines the key market drivers and restraints, as well as evaluates the latest technological advances. The key feature of the review is a detailed analysis of the revenues, market growth rates and market share for the European market and for each of the selected geographic regions, which include: France, Germany, Italy, Spain, the U.K., the Benelux countries, Scandinavia and the Rest of Europe (ROE). The analysis surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the European market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company' s market position. Detailed tables and charts with sales forecasts and market data are also included.

Methodology

The author of this report is a Ph.D. in biochemistry from the University of Liverpool with many decades of experience in science writing and as a medical industry analyst. For this study, information on issues and challenges affecting and influencing the market for POCT products were gathered through an extensive variety of different sources. The editor of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post- doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies.

Report Statistics

  • Publication Date: September 2011
  • Total Number of Pages: 179

Table of Contents

1. Overview

  • 1.1. About This Report
  • 1.2. Scope of this Report
  • 1.3. Methodology
  • 1.4. Executive Summary

2. Background to the European Market for Point of Care Testing (POCT)

  • 2.1. Background and Definition of Point of Care Testing
  • 2.2. POCT Application Areas
    • 2.2.1. POCT in the Primary Care Environment
    • 2.2.2. POCT in the Operating Room
    • 2.2.3. POCT in the Intensive Care Unit (ICU)
    • 2.2.4. POCT in Accident and Emergency (A&E)
    • 2.2.5. POCT in the Patient Transport Setting
    • 2.2.6. POCT in the Home Environment
    • 2.2.7. POCT in the Community
    • 2.2.8. POCT in Sports Medicine
    • 2.2.9. POCT in the Physician' s Office Laboratory (POL)/Home Care Clinic
  • 2.3. Qualitative Market Analysis
    • 2.3.1. Market Drivers
    • 2.3.2. Market Restraints
    • 2.3.3. Advantages of POCT
    • 2.3.4. Disadvantages of POCT
  • 2.4. Regulatory Environment, Issues and Challenges
  • 2.5. Overview of the European Healthcare Systems
  • 2.6. Procurement Process of Point of Care Testing Products
  • 2.7. Secondary Care Structure and Organization within the E.U.
  • 2.8. Product Pricing Policy and Issues
  • 2.9. Technological Advances and Developments
    • 2.9.1. Device Miniaturization and Microfluidic Technologies
    • 2.9.2. Minimally Invasive and Non-Invasive POCT Technologies
    • 2.9.3. Advances in Wireless Technologies
    • 2.9.4. Automation of POCT
    • 2.9.5. Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)
    • 2.9.6. Advances in Informatics Technologies
    • 2.9.7. Pharmacogenetic Testing
    • 2.9.8. Multi Assay Technologies in POCT
  • 2.10. Future Trends and Developments

3. The European Market for Blood Glucose POCT

  • 3.1. Background to POC Blood Glucose Testing
  • 3.2. Types of Blood Glucose Testing
    • 3.2.1. Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG)
    • 3.2.2. Two-Hour Postprandial Blood Sugar or Two-Hour PC
    • 3.2.3. Random Blood Sugar (RBS)
    • 3.2.4. Urine Glucose Test
    • 3.2.5. Blood Glucose Test Strip
    • 3.2.6. Glycosylated Hemoglobin (HbA1C)
    • 3.2.7. Intravenous Glucose Tolerance Test (IVGTT)
    • 3.2.8. Oral Glucose Tolerance Test (OGTT)
  • 3.3. Segmentation of POC Blood Glucose Testing
    • 3.3.1. Continuous Blood Glucose Monitoring (CBGM)
    • 3.3.2. Self-Monitoring Blood Glucose (SMBG) Testing
    • 3.3.3. Minimally Invasive and Non-Invasive Blood Glucose Testing
  • 3.4. Emerging Glucose Monitoring Technologies
    • 3.4.1. Optical Transducer Technologies
    • 3.4.2. Transdermal Sensor Technologies
    • 3.4.3. Invasive Glucose Sensor Technologies
  • 3.5. Review of Selected POC Blood Glucose Monitoring Systems
  • 3.6. Market Revenue Analysis
    • 3.6.1. European Market Revenues Analysis
    • 3.6.2. National Market Revenue Analysis
  • 3.7. Market Share Analysis
    • 3.7.1. European Market Share Analysis
    • 3.7.2. European Market Share Analysis

4. The European Market for Blood Gas and Electrolyte POCT

  • 4.1. Background to POC Blood Gas and Electrolyte Testing
    • 4.1.1. Acid-base Balance and the Lungs
    • 4.1.2. Respiratory Acidosis
    • 4.1.3. Respiratory Alkalosis
    • 4.1.4. Metabolic (or Non-Respiratory) Acidosis
    • 4.1.5. Metabolic (or Non-Respiratory) Alkalosis
    • 4.1.6. Increasing Popularity of POC Blood Gas and Electrolyte Testing
  • 4.2. Market Segmentation
    • 4.2.1. Types of Blood Gas Monitoring Equipment
      • 4.2.1.1. Intermittent Blood Gas Monitoring Equipment
      • 4.2.1.2. Continuous Blood Gas Monitoring Equipment
        • 4.2.1.2.1. Extra-Arterial Blood Gas (EABG) Monitors
        • 4.2.1.2.2. Intra-Arterial Blood Gas (IABG) Monitors
      • 4.2.1.3. Portable, Blood Gas Analyzers
      • 4.2.1.4. Patient Attached, On-Demand Blood Gas Analyzers
  • 4.3. Applications for POCT Blood Gas and Electrolyte Analyzers
  • 4.4. Qualitative Analysis
    • 4.4.1. Market Drivers
    • 4.4.2. Market Restraints
  • 4.5. Emerging Technologies
  • 4.6. Review of Selected Blood Gas and Electrolyte Analyzers
  • 4.7. Market Revenue Analysis
    • 4.7.1. European Market Revenues Analysis
    • 4.7.2. National Market Revenue Analysis
  • 4.8. Market Share Analysis
    • 4.8.1. European Market Share Analysis
    • 4.8.2. National Market Share Analysis

5. The European Market for Rapid Coagulation Testing

  • 5.1. Background to Rapid Coagulation Testing
    • 5.1.1. Hemostasis
    • 5.1.2. Coagulation
      • 5.1.2.1. The Intrinsic Pathway
      • 5.1.2.2. The Extrinsic Pathway
    • 5.1.3. Activation of Prothrombin to Thrombin
  • 5.2. Blood Coagulation Tests
    • 5.2.1. Bleeding Time Tests
    • 5.2.2. Thrombin Time
    • 5.2.3. The Prothrombin Time (PT) Test
    • 5.2.4. The Partial Thromboplastin Time (PPT) Test
    • 5.2.5. The Fibrinogen Test
    • 5.2.6. Standard Test Results
  • 5.3. Qualitative Analysis
    • 5.3.1. Market Drivers
    • 5.3.2. Market Restraints
  • 5.4. Review of Selected POC Rapid Coagulation Analyzers
  • 5.5. Market Revenue Analysis
    • 5.5.1. European Market Revenue Analysis
    • 5.5.2. National Market Revenue Analysis
  • 5.6. Market Share Analysis
    • 5.6.1. European Market Share Analysis
    • 5.6.2. National Market Share Analysis

6. The European Market for POC Cardiac BioMarker Testing

  • 6.1. Background to POC Cardiac Markers Testing
  • 6.2. Cardiac Marker Tests
    • 6.2.1. Creatine Kinase (CK)
    • 6.2.2. Myoglobin
    • 6.2.3. Cardiac Troponins T (TnT), I (TnI) and C (TnC)
    • 6.2.4. C-reactive Protein (CRP)
    • 6.2.5. Homocysteine
  • 6.3. Emerging Markers
    • 6.3.1. B-type Natriuretic Peptide (BNP)
    • 6.3.2. Myeloperoxidase (MPO)
    • 6.3.3. Ischemia Modified Albumin (IMA)
    • 6.3.4. Glycogen Phosphorylase Isoenzyme BB (GPBB)
    • 6.3.5. Fatty Acid-Binding Proteins (FABPs)
  • 6.4. Qualitative Analysis
    • 6.4.1. Market Drivers
    • 6.4.2. Market Restraints
  • 6.5. Review of Selected POC Cardiac Biomarkers Analyzers
  • 6.6. Market Revenue Analysis
    • 6.6.1. European Market Revenue Analysis
    • 6.6.2. National Market Revenue Analysis
  • 6.7. Market Share Analysis
    • 6.7.1. European Market Share Analysis
    • 6.7.2. National Market Share Analysis

7. The European Market for POC Substance Abuse Testing

  • 7.1. Background to POC Substance Abuse Testing
  • 7.2. Substance Abuse Test Types
    • 7.2.1. Urine Substance/Drug Screening
    • 7.2.2. Hair Tests for Substance Abuse and Screening
    • 7.2.3. Blood Tests for Substance Abuse and Screening
    • 7.2.4. Saliva Tests for Substance Abuse and Screening
    • 7.2.5. Sweat Tests for Substance Abuse and Screening
    • 7.2.6. Alcohol Abuse and Screening
  • 7.3. Qualitative Analysis
    • 7.3.1. Market Drivers
    • 7.3.2. Market Restraints
  • 7.4. Review of Selected POC Substance Abuse Analyzers
  • 7.5. Market Revenue Analysis
    • 7.5.1. European Market Revenue Analysis
    • 7.5.2. National Market Revenue Analysis
  • 7.6. Market Share Analysis
    • 7.6.1. European Market Share Analysis
    • 7.6.2. National Market Share Analysis

8. The European Market for POC Infectious Disease Testing

  • 8.1. Background to POC Infectious Disease Testing
  • 8.2. Types of Diagnosis for Infectious Diseases
    • 8.2.1. Microbial Culture
    • 8.2.2. Microscopy
    • 8.2.3. Biochemical Tests
    • 8.2.4. Molecular Diagnostics
  • 8.3. Diagnostic Platforms for Infectious Diseases
    • 8.3.1. Centralized Laboratory Testing for Infectious Diseases
    • 8.3.2. POC Testing for Infectious Diseases
  • 8.4. Emerging Technologies
  • 8.5. Qualitative Analysis
    • 8.5.1. Market Drivers
    • 8.5.2. Market Restraints
  • 8.6. Review of Selected POC Infectious Disease Testing Devices
  • 8.7. Market Revenue Analysis
    • 8.7.1. European Market Revenue Analysis
    • 8.7.2. National Market Revenue Analysis
  • 8.8. Market Share Analysis
    • 8.8.1. European Market Share Analysis
    • 8.8.2. National Market Share Analysis

9. The European Market for POC Urine Strip Testing

  • 9.1. Background to POC Urine Strip Testing
  • 9.2. Emerging Technologies
  • 9.3. Review of Selected POC Urine Strip Testing
  • 9.4. Market Revenue Analysis
    • 9.4.1. European Market Revenue Analysis
    • 9.4.2. National Market Revenue Analysis
  • 9.5. Market Share Analysis
    • 9.5.1. European Market Share Analysis
    • 9.5.2. National Market Share Analysis

10. The European Market for POC Pregnancy Testing

  • 10.1. Background to POC Pregnancy Testing
  • 10.2. Review of Selected POC Pregnancy Testing Devices
  • 10.3. Market Revenue Analysis
    • 10.3.1. European Market Revenue Analysis
    • 10.3.2. National Market Revenue Analysis
  • 10.4. Market Share Analysis
    • 10.4.1. European Market Share Analysis
    • 10.4.2. National Market Share Analysis

11. The European Market for POC Fecal Occult Testing

  • 11.1. Background to POC Fecal Occult Testing
  • 11.2. Review of Selected POC Fecal Occult Testing Devices
  • 11.3. Market Revenue Analysis
    • 11.3.1. European Market Revenue Analysis
    • 11.3.2. National Market Revenue Analysis
  • 11.4. Market Share Analysis
    • 11.4.1. European Market Share Analysis
    • 11.4.2. National Market Share Analysis

12. The European Market for POC Cholesterol Testing

  • 12.1. Background to POC Cholesterol Testing
  • 12.2. POC Cholesterol Testing Devices
    • 12.2.1. Review of Selected POC Cholesterol Testing Devices
    • 12.2.2. Product Comparison of Leading Suppliers
    • 12.2.3. Launch Dates of Leading Products in Europe
  • 12.3. Market Revenue Analysis
    • 12.3.1. European Market Revenue Analysis
    • 12.3.2. National Market Revenue Analysis
  • 12.4. Market Share Analysis
    • 12.4.1. European Market Share Analysis
    • 12.4.2. National Market Share Analysis

13. Profile of Leading Suppliers

  • 13.1. Abaxis, Inc.
  • 13.2. Abbott Laboratories
  • 13.3. ACON Laboratories, Inc.
  • 13.4. AgaMatrix, Inc.
  • 13.5. Alere, Inc.
  • 13.6. Bayer AG
  • 13.7. LifeScan (Johnson & Johnson)
  • 13.8. International Technidyne Corporation (ITC) Nexus Dx (Warburg Pincus, LLC)
  • 13.9. NOVA Biomedical
  • 13.10. F. Hoffman-La Roche Ltd.
  • 13.11. A Menarini Diagnostics
  • 13.12. Medtronic, Inc.
  • 13.13. Radiometer Medical (Danaher Corporation)
  • 13.14. Instrumentation Laboratory (IL)/Werfen Group
  • 13.15. Siemens

14. Glossary of Abbreviations and Acronyms

INDEX OF FIGURES

  • Figure 2.1: Available forms of Connectivity Technology for POCT Devices
  • Figure 2.2: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device Category
  • Figure 5.1: The Coagulation Cascade
  • Figure 5.2: Coagulation Testing

INDEX OF TABLES

  • Table 1.1: European Revenue Analysis and Forecasts for POC Market, 2007-2017
  • Table 1.2: Segment Revenue Analysis and Forecasts for POC Market, 2007-2017
  • Table 1.3: European Revenue Forecasts for POC Market, 2007-2017
  • Table 1.4: European Market Share Analysis for POC Market, 2010
  • Table 2.1: Total Expenditure on Healthcare, Percentage GDP of Selected Countries, 2002-2008
  • Table 2.2: Models of Public-Private Partnership in Hospital Provision
  • Table 2.3: Common Genotype Techniques
  • Table 3.1: Summary of Emerging Glucose Sensor Technologies, 2011
  • Table 3.2: Selected POC Blood Glucose Monitoring Systems, 2011
  • Table 3.3: European Revenue Forecasts for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 3.4: National Revenue Forecasts by Country for POC Blood Glucose Monitoring Systems, 2007-2017
  • Table 3.5: European Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.6: French Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.7: German Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.8: Italian Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.9: Spanish Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.10: U.K. Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.11: Benelux Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.12: Scandinavian Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 3.13: Rest-of-Europe Market Share Analysis for POC Blood Glucose Monitoring Systems, 2010
  • Table 4.1: Selected POC Blood Gas and Electrolyte Analyzers, 2011
  • Table 4.2: European Revenue Forecasts for POC Blood Gas Analysis Systems, 2007-2017
  • Table 4.3: National Revenue Forecasts by Country for POC Blood Gas Analysis Systems, 2007-2017
  • Table 4.4: European Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.5: French Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.6: German Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.7: Italian Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.8: Spanish Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.9: U.K. Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.10: Benelux Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.11: Scandinavian Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 4.12: Rest-of-Europe Market Share Analysis for POC Blood Gas Analysis Systems, 2010
  • Table 5.1: Selected POC Rapid Coagulation Analyzers, 2011
  • Table 5.2: European Revenue Forecasts for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 5.3: National Revenue Forecasts by Country for POC Rapid Coagulation Analyzer Systems, 2007-2017
  • Table 5.4: European Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.5: French Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.6: German Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.7: Italian Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.8: Spanish Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.9: U.K. Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.10: Benelux Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.11: Scandinavian Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 5.12: Rest-of-Europe Market Share Analysis for POC Rapid Coagulation Analyzer Systems, 2010
  • Table 6.1: Selected POC Cardiac Biomarkers, 2011
  • Table 6.2: European Revenue Forecasts for POC Cardiac Marker Devices, 2007-2017
  • Table 6.3: National Revenue Forecasts by Country for POC Cardiac Marker Devices, 2007-2017
  • Table 6.4: European Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.5: French Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.6: German Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.7: Italian Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.8: Spanish Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.9: U.K. Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.10: Benelux Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.11: Scandinavian Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 6.12: Rest-of-Europe Market Share Analysis for POC Cardiac Marker Devices, 2010
  • Table 7.1: Selected POC Substance/Drug Abuse Testing Devices, 2011
  • Table 7.2: European Revenue Forecasts for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 7.3: National Revenue Forecasts by Country for POC Substance/Drug Abuse Testing Device Market, 2007-2017
  • Table 7.4: European Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.5: French Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.6: German Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.7: Italian Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.8: Spanish Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.9: U.K. Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.10: Benelux Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.11: Scandinavian Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 7.12: Rest-of-Europe Market Share Analysis for POC Substance/Drug Abuse Testing Device Market, 2010
  • Table 8.1: Selected POC Infectious Disease Testing Devices, 2011
  • Table 8.2: European Revenue Forecasts for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 8.3: National Revenue Forecasts by Country for POC Infectious Disease Testing Devices Market, 2007-2017
  • Table 8.4: European Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.5: French Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.6: German Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.7: Italian Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.8: Spanish Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.9: U.K. Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.10: Benelux Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.11: Scandinavian Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 8.12: Rest-of-Europe Market Share Analysis for POC Infectious Disease Testing Devices, 2010
  • Table 9.1: Selected POC Urine Strip Testing, 2011
  • Table 9.2: European Revenue Forecasts for POC Urine Strip Testing Products Market, 2007-2017
  • Table 9.3: National Revenue Forecasts by Country for POC Urine Strip Testing Products Market, 2007-2017
  • Table 9.4: European Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.5: French Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.6: German Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.7: Italian Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.8: Spanish Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.9: U.K. Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.10: Benelux Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.11: Scandinavian Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 9.12: Rest-of-Europe Market Share Analysis for POC Urine Strip Testing Products, 2010
  • Table 10.1: Selected POC Pregnancy Testing Devices, 2011
  • Table 10.2: European Revenue Forecasts for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 10.3: National Revenue Forecasts by Country for POC Pregnancy Testing Devices Market, 2007-2017
  • Table 10.4: European Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.5: French Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.6: German National Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.7: Italian Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.8: Spanish Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.9: U.K. Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.10: Benelux Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.11: Scandinavian Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 10.12: Rest-of-Europe Market Share Analysis for POC Pregnancy Testing Devices, 2010
  • Table 11.1: Selected POC Fecal Occult Testing Devices, 2011
  • Table 11.2: European Revenue Forecasts for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 11.3: National Revenue Forecasts by Country for POC Fecal Occult Testing Devices Market, 2007-2017
  • Table 11.4: European Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.5: French Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.6: German Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.7: Italian Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.8: Spanish Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.9: U.K. Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.10: Benelux Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.11: Scandinavian Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 11.12: Rest-of-Europe Market Share Analysis for POC Fecal Occult Testing Devices, 2010
  • Table 12.1: Selected POC Cholesterol Testing Devices, 2011
  • Table 12.2: European Revenue Forecasts for POC Cholesterol Testing Products Market, 2007-2017
  • Table 12.3: National Revenue Forecasts by Country for POC Cholesterol Testing Products Market, 2007-2017
  • Table 12.4: European Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.5: French Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.6: German Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.7: Italian Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.8: Spanish Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.9: U.K. Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.10: Benelux Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.11: Scandinavian Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 12.12: Rest-of-Europe Market Share Analysis for POC Cholesterol Testing Products Market, 2010
  • Table 13.1: Abaxis, Inc. Net Sales by Business Sector, 2008-2010
  • Table 13.2: Abaxis, Inc. Net Sales by Geographic Region, 2008-2010
  • Table 13.3: Abbott Laboratories Net Sales by Business Sector, 2008-2010
  • Table 13.4: Abbott Laboratories Net Sales by Geographic Region, 2008-2010
  • Table 13.5: Alere, Inc. Net Sales by Business Sector, 2008-2010
  • Table 13.6: Alere, Inc. Net Sales by Geographic Region, 2008-2010
  • Table 13.7: Bayer AG Net Sales by Business Sector, 2008-2010
  • Table 13.8: Bayer AG Net Sales by Geographic Region, 2008-2010
  • Table 13.9: Johnson & Johnson Net Sales by Major Medical and Diagnostics Businesses, 2008-2010
  • Table 13.10: Roche Group Net Sales by Business Sector, 2008-2010
  • Table 13.11: Roche Group Net Sales by Geographic Region (Pharmaceuticals), 2009 and 2010
  • Table 13.12: Roche Group Net Sales by Sub-Division (Diagnostics), 2008-2010
  • Table 13.13: Medtronic Net Sales by Segment, 2008-2010
  • Table 13.14: Danaher Corporation Net Sales by Business Sector, 2008-2010
  • Table 13.15: Danaher Corporation Net Sales by Geographic Region, 2008-2010
Back to Top